Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Florida: - Mount Sinai Comprehensive Cancer Center at Aventura — Aventura, Florida
- Morton Plant Hospital — Clearwater, Florida
- Broward Health North — Deerfield Beach, Florida
- Holy Cross Hospital — Fort Lauderdale, Florida
- Broward Health Medical Center — Fort Lauderdale, Florida
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Florida: - Morton Plant Hospital — Clearwater, Florida
- Mayo Clinic in Florida — Jacksonville, Florida
- Jupiter Medical Center — Jupiter, Florida
- The Watson Clinic — Lakeland, Florida
- Mount Sinai Medical Center — Miami Beach, Florida
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Florida: - Halifax Health Medical Center-Centers for Oncology — Daytona Beach, Florida
- UF Health Cancer Institute - Gainesville — Gainesville, Florida
- Mayo Clinic in Florida — Jacksonville, Florida
- Tallahassee Memorial HealthCare — Tallahassee, Florida
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…
Sponsor: AstraZeneca
NCT ID: NCT05952557
Sites in Florida: - Research Site — Clearwater, Florida
- Research Site — Fort Myers, Florida
- Research Site — Gainesville, Florida
- Research Site — Jacksonville, Florida
- Research Site — Orlando, Florida
Phase 3 Recruiting Academic/Other
The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effects and stay on treatment longer, to der…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT06377852
Sites in Florida: - Miami Cancer Institute — Miami, Florida
- Miami Cancer Institute — Plantation, Florida
Phase 3 Recruiting Industry
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBC…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05827081
Sites in Florida: - Holy Cross Health — Fort Lauderdale, Florida
- Memorial Cancer Institute — Hollywood, Florida
- Ocala Research Institute, Inc — Ocala, Florida
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…
Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in Florida: - Research Site — Jacksonville, Florida
- Research Site — Miami, Florida
- Research Site — Palm Bay, Florida
- Research Site — Plantation, Florida
Phase 3 Recruiting Industry
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06065748
Sites in Florida: - AdventHealth Altamonte — Altamonte Springs, Florida
- Florida Cancer Specialists - Broadway — Fort Myers, Florida
- Cancer Specialists of North Florida — Jacksonville, Florida
- Florida Cancer Specialists - North;725 6th Ave South (St. Petersburg) — St. Petersburg, Florida
- Comprehensive Hematology Oncology — St. Petersburg, Florida
Phase 3 Recruiting Academic/Other
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…
Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in Florida: - UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- UM Sylvester Comprehensive Cancer Center at Doral — Doral, Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
Phase 3 Recruiting Industry
The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth fa…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312176
Sites in Florida: - AdventHealth Altamonte Springs ( Site 0021) — Altamonte Springs, Florida
- University of Florida College of Medicine ( Site 0063) — Gainesville, Florida
- Orlando Health Cancer Institute ( Site 0011) — Orlando, Florida
Phase 3 Recruiting Industry
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…
Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in Florida: - University of Miami - Sylvester Comprehensive Cancer Center — Miami, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in Florida: - Local Institution - 0296 — Pembroke Pines, Florida
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in Florida: - Cancer Specialists of North Florida - Jacksonville — Jacksonville, Florida
- Tallahassee Memorial HealthCare — Tallahassee, Florida
- Moffitt Cancer Center-McKinley Campus — Tampa, Florida
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Florida: - UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- Broward Health Medical Center — Fort Lauderdale, Florida
- UF Health Cancer Institute - Gainesville — Gainesville, Florida
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, Phase 1b/2 trial in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced/metastatic breast cancer. The phase 1b part of the trial will determine the reco…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT05563220
Sites in Florida: - Advent Health (Florida Hospital) - Altamonte Springs — Altamonte Springs, Florida
- Mayo Clinic - Jacksonville — Jacksonville, Florida
- Ocala Oncology — Ocala, Florida
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Florida: - Advanced Research LLC — Coral Springs, Florida
- The Oncology Institute of Hope and Innovation — Lakeland, Florida
- D&H Cancer Research Center LLC — Margate, Florida
- HCA Mercy Hospital — Miami, Florida
- BRCR Medical Center Inc. — Plantation, Florida
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in Florida: - Mayo Clinic Florida — Jacksonville, Florida
- Cancer Specialists of North Florida — Jacksonville, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…
Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Florida: - Florida Cancer Specialists ORLANDO/DDU — Lake Mary, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor …
Sponsor: Eisai Inc.
NCT ID: NCT04300556
Sites in Florida: - University of Miami — Coral Gables, Florida
- Moffitt Cancer Center and Research Institute — Tampa, Florida
Phase 2 Recruiting Industry
The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT07102381
Sites in Florida: - The Oncology Institute — Lakeland, Florida
Phase 2 Recruiting Industry
This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastases. Patients will be enrolled to receiv…
Sponsor: Biostar Pharma, Inc.
NCT ID: NCT06764940
Sites in Florida: - Biosresearch Partner — Hialeah, Florida
- D&H Cancer Research Center — Margate, Florida
Phase 1, Phase 2 Recruiting Industry
This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, six co…
Sponsor: Hoffmann-La Roche
NCT ID: NCT03424005
Sites in Florida: - H. Lee Moffitt Cancer Center and Research Inst. — Tampa, Florida
Phase 2 Recruiting Academic/Other
This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The nam…
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04468061
Sites in Florida: - Miami Cancer Institute at Baptist Health (Kendall) — Miami, Florida
- Miami Cancer Institute at Baptist Health — Plantation, Florida
Phase 1, Phase 2 Recruiting Industry
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specif…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT05732831
Sites in Florida: - Florida Cancer Specialists & Research Institute — Lake Mary, Florida
- Sylvester Comprehensive Cancer Center — Miami, Florida
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06618287
Sites in Florida: - University of Miami Hospital and Clinics, Sylvester Cancer Center — Miami, Florida